PKCβ inhibition with ruboxistaurin reduces oxidative stress and attenuates left ventricular hypertrophy and dysfuntion in rats with streptozotocin-induced diabetes

Clinical Science

Volumn 122, Issue 4, 2012, Pages 161-173

  Liu, Yanan ^a   Lei, Shaoqing ^a   Gao, Xia ^a   Mao, Xiaowen ^a   Wang, Tingting ^a   Wong, Gordon T ^a   Vanhoutte, Paul M ^a   Irwin, Michael G ^a   Xia, Zhengyuan ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Diabetic cardiomyopathy; Left ventricular hypertrophy; Oxidative stress; Protein kinase c ; Ruboxistaurin

Indexed keywords

ACETYLCYSTEINE; ISOPROSTANE DERIVATIVE; PROTEIN KINASE C BETA; PROTEIN P22; PROTEIN P67; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RUBOXISTAURIN; STREPTOZOCIN; SUPEROXIDE; SUPEROXIDE DISMUTASE; 15 F2T ISOPROSTANE; 15-F2T-ISOPROSTANE; INDOLE DERIVATIVE; MALEIMIDE DERIVATIVE; PROTEIN KINASE C; SCAVENGER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG SELECTIVITY; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; ENZYME INHIBITION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE RELAXATION; HEART MUSCLE CELL; IMMUNOASSAY; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STREPTOZOCIN DIABETES; WESTERN BLOTTING; ANIMAL; BLOOD; COMPARATIVE STUDY; DIABETIC CARDIOMYOPATHY; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ECHOGRAPHY; ENZYME ACTIVATION; ENZYMOLOGY; EXPERIMENTAL DIABETES MELLITUS; METABOLISM; SPRAGUE DAWLEY RAT;

ACETYLCYSTEINE; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC CARDIOMYOPATHIES; DRUG EVALUATION, PRECLINICAL; ENZYME ACTIVATION; FREE RADICAL SCAVENGERS; HYPERTROPHY, LEFT VENTRICULAR; INDOLES; ISOPROSTANES; MALE; MALEIMIDES; MYOCYTES, CARDIAC; NADPH OXIDASE; OXIDATIVE STRESS; PROTEIN KINASE C; RATS; RATS, SPRAGUE-DAWLEY; SUPEROXIDES;

EID: 84555203690     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20110176     Document Type: Article

References (57)

1. Asghar, O., Al-Sunni, A., Khavandi, K., Khavandi, A., Withers, S., Greenstein, A., Heagerty, A. M. and Malik, R. A. (2009) Diabetic cardiomyopathy. Clin. Sci. 116, 741-760
2. Fang, Z. Y., Prins, J. B. and Marwick, T. H. (2004) Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr. Rev. 25, 543-567
3. Rodrigues, B., Cam, M. C. and McNeill, J. H. (1998) Metabolic disturbances in diabetic cardiomyopathy. Mol. Cell. Biochem. 180, 53-57
4. Frustaci, A., Kajstura, J., Chimenti, C., Jakoniuk, I., Leri, A., Maseri, A., Nadal-Ginard, B. and Anversa, P. (2000) Myocardial cell death in human diabetes. Circulation Research 87, 1123-1132
5. Pang, Y., Hunton, D. L., Bounelis, P. and Marchase, R. B. (2002) Hyperglycemia inhibits capacitative calcium entry and hypertrophy in neonatal cardiomyocytes. Diabetes 51, 3461-3467
6. Xia, Z., Kuo, K. H., Nagareddy, P. R., Wang, F., Guo, Z., Guo, T., Jiang, J. and McNeill, J. H. (2007) N-acetylcysteine attenuates PKCβ2 overexpression and myocardial hypertrophy in streptozotocin-induced diabetic rats. Cardiovasc. Res. 73, 770-782
7. Laakso, M. (1999) Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 48, 937-942
8. Laakso, M. (1999) Hyperglycemia as a risk factor for cardiovascular disease in type 2 diabetes. Prim. Care. 26, 829-839
9. Finkel, T. (2003) Oxidant signals and oxidative stress. Curr. Opin. Cell Biol. 15, 247-254
10. Hirotani, S., Otsu, K., Nishida, K., Higuchi, Y., Morita, T., Nakayama, H., Yamaguchi, O., Mano, T., Matsumura, Y., Ueno, H. et al. (2002) Involvement of nuclear factor-κB and apoptosis signal-regulating kinase 1 in G-protein-coupled receptor agonist-induced cardiomyocyte hypertrophy. Circulation 105, 509-515
11. Pimentel, D. R., Amin, J. K., Xiao, L., Miller, T., Viereck, J., Oliver-Krasinski, J., Baliga, R., Wang, J., Siwik, D. A., Singh, K. et al. (2001) Reactive oxygen species mediate amplitude-dependent hypertrophic and apoptotic responses to mechanical stretch in cardiac myocytes. Circ. Res. 89, 453-460
12. Lassegue, B. and Clempus, R. E. (2003) Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am. J. Physiol. Regul. Integr. Comp. Physiol. 285, R277-R297
13. Murdoch,C. E., Zhang, M.,Cave, A. C. and Shah, A. M. (2006) NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure. Cardiovasc. Res. 71, 208-215
14. Griendling, K. K., Sorescu, D. and Ushio-Fukai, M. (2000) NAD(P)H oxidase: role in cardiovascular biology and disease. Circ. Res. 86, 494-501
15. Suzuki, Y. and Lehrer, R. I. (1980) NAD(P)H oxidase activity in human neutrophils stimulated by phorbol myristate acetate. J. Clin. Invest. 66, 1409-1418
16. Kang, N., Alexander, G., Park, J. K., Maasch, C., Buchwalow, I., Luft, F. C. and Haller, H. (1999) Differential expression of protein kinase C isoforms in streptozotocin-induced diabetic rats. Kidney Int. 56, 1737-1750
17. Inoguchi, T., Sonta, T., Tsubouchi, H., Etoh, T., Kakimoto, M., Sonoda, N., Sato, N., Sekiguchi, N., Kobayashi, K., Sumimoto, H. et al. (2003) Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: role of vascular NAD(P)H oxidase. J. Am. Soc. Nephrol. 14, S227-S232
18. Guo, Z., Xia, Z., Jiang, J. and McNeill, J. H. (2007) Downregulation of NADPH oxidase, antioxidant enzymes, and inflammatory markers in the heart of streptozotocin-induced diabetic rats by N-acetyl-L-cysteine. Am. J. Physiol. Heart Circ. Physiol. 292, H1728-H1736
19. Wakasaki, H., Koya, D., Schoen, F. J., Jirousek, M. R., Ways, D. K., Hoit, B. D., Walsh, R. A. and King, G. L. (1997) Targeted overexpression of protein kinase Cβ2 isoform in myocardium causes cardiomyopathy. Proc. Natl. Acad. Sci. U.S.A. 94, 9320-9325
20. Tuttle, K. R. and Anderson, P. W. (2003) A novel potential therapy for diabetic nephropathy and vascular complications: Protein kinase Cβ inhibition. Am. J. Kidney Dis. 42, 456-465
21. Gutterman, D. D. (2002) Vascular dysfunction in hyperglycemia: is protein kinase C the culprit? Circ. Res. 90, 5-7
22. Avignon, A. and Sultan, A. (2006) PKC-B inhibition: a new therapeutic approach for diabetic complications? Diabetes Metab. 32, 205-213
23. Connelly, K. A., Kelly, D. J., Zhang, Y., Prior, D. L., Advani, A., Cox, A. J., Thai, K., Krum, H. and Gilbert, R. E. (2009) Inhibition of protein kinase C-β by ruboxistaurin preserves cardiac function and reduces extracellular matrix production in diabetic cardiomyopathy. Circ. Heart Failure 2, 129-137
24. Fein, F. S. (1990) Diabetic cardiomyopathy. Diabetes Care 13, 1169-1179
25. Nakagami, H., Kaneda, Y., Ogihara, T. and Morishita, R. (2005) Endothelial dysfunction in hyperglycemia as a trigger of atherosclerosis. Curr. Diabetes Rev. 1, 59-63
26. Xia, Z., Guo, Z., Nagareddy, P. R., Yuen, V., Yeung, E. and McNeill, J. H. (2006) Antioxidant N-acetylcysteine restores myocardial Mn-SOD activity and attenuates myocardial dysfunction in diabetic rats. Eur. J. Pharmacol. 544, 118-125.
27. 2t-isoprostane in the myocardium and plasma in Type 1 diabetic rats. FASEB J. 24 (Suppl), 572.1
28. Ishii, H., Jirousek, M. R., Koya, D., Takagi, C., Xia, P., Clermont, A., Bursell, S. E., Kern, T. S., Ballas, L. M., Heath, W. F. et al. (1996) Amelioration of vascular dysfunctions in diabetic rats by an oral PKCβ inhibitor. Science 272, 728-731
29. Nagareddy, P. R., Soliman, H., Lin, G., Rajput, P. S., Kumar, U., McNeill, J. H. and MacLeod, K. M. (2009) Selective inhibition of protein kinase Cβ2 attenuates inducible nitric oxide synthase-mediated cardiovascular abnormalities in streptozotocin-induced diabetic rats. Diabetes 58, 2355-2364
30. Harada, K., Komuro, I., Shiojima, I., Hayashi, D., Kudoh, S., Mizuno, T., Kijima, K., Matsubara, H., Sugaya, T., Murakami, K. and Yazaki, Y. (1998) Pressure overload induces cardiac hypertrophy in angiotensin II type 1A receptor knockout mice. Circulation 97, 1952-1959
31. Di Zhang, A., Cat, A. N. D., Soukaseum, C., Escoubet, B., Cherfa, A., Messaoudi, S., Delcayre, C., Samuel, J. L. and Jaisser, F. (2008) Cross-talk between mineralocorticoid and angiotensin II signaling for cardiac remodeling. Hypertension 52, 1060-1067
32. Fiordaliso, F., Bianchi, R., Staszewsky, L., Cuccovillo, I., Doni, M., Laragione, T., Salio, M., Savino, C., Melucci, S., Santangelo, F. et al. (2004) Antioxidant treatment attenuates hyperglycemia-induced cardiomyocyte death in rats. J. Mol. Cell. Cardiol. 37, 959-968
33. Wu, R., Laplante, M. A. and De Champlain, J. (2004) Prevention of angiotensin II-induced hypertension, cardiovascular hypertrophy and oxidative stress by acetylsalicylic acid in rats. J. Hypertens. 22, 793-801
34. Li, Y. L., Gao, L., Zucker, I. H. and Schultz, H. D. (2007) NADPH oxidase-derived superoxide anion mediates angiotensin II-enhanced carotid body chemoreceptor sensitivity in heart failure rabbits. Cardiovasc. Res. 75, 546-554
35. 2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc. Natl. Acad. Sci. U.S.A. 87, 9383-9387
36. Huang, Z., Zhong, X., Irwin, M. G., Ji, S., Wong, G. T., Liu, Y., Xia, Z. Y., Finegan, B. A. and Xia, Z. (2011) Synergy of isoflurane preconditioning and propofol postconditioning reduces myocardial reperfusion injury in patients. Clin. Sci. 121, 57-69
37. Inoguchi, T., Battan, R., Handler, E., Sportsman, J. R., Heath, W. and King, G. L. (1992) Preferential elevation of protein kinase C isoformβ II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc. Natl. Acad. Sci. U.S.A. 89, 11059-11063
38. Levy, D., Savage, D. D., Garrison, R. J., Anderson, K. M., Kannel, W. B. and Castelli, W. P. (1987) Echocardiographic criteria for left-ventricular hypertrophy: the Framingham Heart-Study. Am. J. Cardiol. 59, 956-960
39. Lorell, B. H. and Carabello, B. A. (2000) Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation 102, 470-479
40. Li, J. M., Gall, N. P., Grieve, D. J., Chen, M. and Shah, A. M. (2002) Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension 40, 477-484
41. Chang, J. P., Chen, M. C., Liu, W. H., Yang, C. H., Chen, C. J., Chen, Y. L., Pan, K. L., Tsai, T.H. and Chang, H. W. (2011) Atrial myocardial nox2 containing NADPH oxidase activity contribution to oxidative stress in mitral regurgitation: potential mechanism for atrial remodeling. Cardiovasc. Pathol. 20, 99-106
42. Hayashi, T., Yamashita, C., Matsumoto, C., Kwak, C. J., Fujii, K., Hirata, T., Miyamura, M., Mori, T., Ukimura, A., Okada, Y. et al. (2008) Role of gp91phox-containing NADPH oxidase in left ventricular remodeling induced by intermittent hypoxic stress. Am. J. Physiol. Heart Circ. Physiol. 294, H2197-H2203
43. Cave, A. C., Brewer, A. C., Narayanapanicker, A., Ray, R., Grieve, D. J., Walker, S. and Shah, A. M. (2006) NADPH oxidases in cardiovascular health and disease. Antioxid. Redox Signaling 8, 691-728
44. Brandes, R. P. and Kreuzer, J. (2005) Vascular NADPH oxidases: molecular mechanisms of activation. Cardiovasc. Res. 65, 16-27
45. Guo, M. Z.,Wu, M. H., Korompai, F. and Yuan, S. Y. (2003) Upregulation of PKC genes and isozymes in cardiovascular tissues during early stages of experimental diabetes. Physiol. Genomics 12, 139-146
46. Bowman, J. C., Steinberg, S. F., Jiang, T. R., Geenen, D. L., Fishman, G. I. and Buttrick, P. M. (1997) Expression of protein kinase Cβ in the heart causes hypertrophy in adult mice and sudden death in neonates. J. Clin. Invest. 100, 2189-2195
47. Kitada, M., Koya, D., Sugimoto, T., Isono, M., Araki, S., Kashiwagi, A. and Haneda, M. (2003) Translocation of glomerular p47phox and p67phox by protein kinase C-β activation is required for oxidative stress in diabetic nephropathy. Diabetes 52, 2603-2614
48. Dekker, L. V., Leitges, M., Altschuler, G., Mistry, N., McDermott, A., Roes, J. and Segal, A. W. (2000) Protein kinase C-β contributes to NADPH oxidase activation in neutrophils. Biochem. J. 347, 285-289
49. phox. Eur. J. Clin. Invest. 39, 28-28
50. phox phosphorylation. J. Biol. Chem. 275, 28406-28412
51. Liu, Q., Chen, X., Macdonnell, S. M., Kranias, E. G., Lorenz, J. N., Leitges, M., Houser, S. R. and Molkentin, J. D. (2009) Protein kinase Cα, but not PKCβ or PKCγ, regulates contractility and heart failure susceptibility: implications for ruboxistaurin as a novel therapeutic approach. Circ. Res. 105, 194-200
52. Idris, I. and Donnelly, R. (2006) Protein kinase Cβ inhibition: A novel therapeutic strategy for diabetic microangiopathy. Diab. Vasc. Dis. Res. 3, 172-178
53. Baynes, J.W. (1991) Role of oxidative stress in development of complications in diabetes. Diabetes 40, 405-412
54. Davi, G., Ciabattoni, G., Consoli, A., Mezzetti, A., Falco, A., Santarone, S., Pennese, E., Vitacolonna, E., Bucciarelli, T., Costantini, F. et al. (1999) In vivo formation of 8-iso-prostaglandin f2α and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 99, 224-229
55. 2t isoprostane concentrations are increased during acute fructose loading in type 2 diabetes. Diabetes Metab. 34, 148-154
56. Montero, A., Munger, K. A., Khan, R. Z., Valdivielso, J. M., Morrow, J. D., Guasch, A., Ziyadeh, F. N. and Badr, K. F. (2000) F2-isoprostanes mediate high glucose-induced TGF-β synthesis and glomerular proteinuria in experimental type I diabetes. Kidney Int. 58, 1963-1972
57. Shirpoor, A., Salami, S., Khadem-Ansari, M. H., Ilkhanizadeh, B., Pakdel, F. G. and Khademvatani, K. (2009) Cardioprotective effect of vitamin E: rescues of diabetes-induced cardiac malfunction, oxidative stress, and apoptosis in rat. J. Diabetes Complications 23, 310-316